Since targeting the classical TGF-β1-Smad pathway has not proven efficacious for treatment or prevention of peritoneal fibrosis, the targets identified here may serve in development of new prognostic tools and therapeutics for peritoneal dialysis patients. The gene discussed is TGFB1; the disease is Peritoneal Fibrosis.